News | December 18, 2023
Biocon Biologics concludes integration of acquired Biosimilars business in 120 countries
10+ emerging markets, Japan & ANZ transition in final phase
10+ emerging markets, Japan & ANZ transition in final phase
Laurus Synthesis receives Form 483 with 5 observations from USFDA
Biocon Biologics is one among the three pharmaceutical companies from India to be featured on this year's list
Receives registration of Valganciclovir powder for oral solution in Germany
Expansion of presence in India with electrical safety, electromagnetic compatibility and medical device biocompatibility, toxicity and microbiology testing and certification services
Atlas Life Sciences (India) has successfully commenced the commercial production of API - Intermediate at its new plant at Chhatral,
The exclusive agreement also includes development, regulatory, and commercialization milestone payments based on the successful outcome
This acquisition marks Max Healthcare's entry into Lucknow
Dr. Reddy's will make a US$ 7.5 million upfront payment to Coya
The agreement includes an upfront payment of US$15 million, regulatory and commercial milestones, and royalties
Subscribe To Our Newsletter & Stay Updated
